Dynamics of SARS-CoV-2 mutations reveals regional-specificity and similar trends of N501 and high-frequency mutation N501Y in different levels of control measures

Abstract

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This disease has spread globally, causing more than 161.5 million cases and 3.3 million deaths to date. Surveillance and monitoring of new mutations in the virus’ genome are crucial to our understanding of the adaptation of SARS-CoV-2. Moreover, how the temporal dynamics of these mutations is influenced by control measures and non-pharmaceutical interventions (NPIs) is poorly understood. Using 1,058,020 SARS-CoV-2 from sequenced COVID-19 cases from 98 countries (totaling 714 country-month combinations), we perform a normalization by COVID-19 cases to calculate the relative frequency of SARS-CoV-2 mutations and explore their dynamics over time. We found 115 mutations estimated to be present in more than 3% of global COVID-19 cases and determined three types of mutation dynamics: high-frequency, medium-frequency, and low-frequency. Classification of mutations based on temporal dynamics enable us to examine viral adaptation and evaluate the effects of implemented control measures in virus evolution during the pandemic. We showed that medium-frequency mutations are characterized by high prevalence in specific regions and/or in constant competition with other mutations in several regions. Finally, taking N501Y mutation as representative of high-frequency mutations, we showed that level of control measure stringency negatively correlates with the effective reproduction number of SARS-CoV-2 with high-frequency or not-high-frequency and both follows similar trends in different levels of stringency.

RNA Interference Approach Is a Good Strategy against SARS-CoV-2

“…In addition, monoclonal antibody-based COVID-19 treatments, including bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, and bebtelovimab; only bebtelovimab has been reported to retain its efficacy against all SARS-CoV-2 variants [ 18 ]. However, the high mutation frequency of the virus allows it to evade these preventive and therapeutic strategies [ 19 ]. Therefore, strategies that can adapt in response to the high mutation frequency of SARS-CoV-2 are urgently needed.…”

COVID-19 Whole-Genome Resequencing with Redundant Tiling PCR and Subtract-Based Amplicon Normalization Successfully Characterized SARS-CoV-2 Variants in Clinical Specimens

“…The genetic epidemiology of the SARS-CoV-2 virus sequences in the USA demonstrated a mutation rate of 6.7 × 10 −4 per site per year, similar to other RNA viruses [ 24 ]. It also has some hotspots under positive selection, especially in the S and N regions [ 24 , 25 ]. At this rate, mutations in the primer sequence are inevitable.…”

COVID-19 Vaccine: Between Myth and Truth

“…The more mutations that occur, the more likely it is that variants will appear. Vaccines are able to decrease the viral load in case of infection, thereby reducing the number of reproduction cycles of the virus by decreasing the possibility of new mutations and the emergence of new variants [ 27 , 28 ].…”